PLX

Protalix Biotherapeutics Inc. is a biopharmaceutical company headquartered in Karmiel, Israel, dedicated to developing and commercializing innovative recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression system. The company is strategically focused on addressing unmet medical needs across emerging markets, notably in Israel, Brazil, and Latin America, with a diverse pipeline aimed at treating various conditions. With a strong commitment to innovation and expansion, Protalix is well-positioned to capitalize on growth opportunities in the biotechnology sector, offering significant potential for enhanced patient outcomes and value creation for institutional investors.